Facebook Twitter LinkedIn Email Print
By AuntMinnie.com staff writers
November 27, 2016

GE Healthcare and molecular breast imaging developer Dilon Diagnostics announced the U.S. Food and Drug Administration (FDA) clearance of GE's molecular breast imaging (MBI) localization accessory for breast biopsy.

Dilon is the exclusive distributor of GE's Discovery NM750b molecular breast imaging system in North America. The system is designed to measure and image the distribution of selected single photon emission radioisotopes to aid in lesion evaluation. The MBI localization accessory complements the Discovery NM750b breast imaging system, which is designed to locate, in 3D, breast lesions using information from stereotactic pairs of 2D images.

The Discovery NM750b system and the breast biopsy accessory will be presented at RSNA 2016 in Chicago.

Dilon, GE ink distribution deal
Molecular breast imaging developer Dilon Diagnostics has signed on to be the exclusive distributor of GE Healthcare's Discovery NM750b molecular breast...
GE Healthcare sees strong Q3 growth in profit, revenue
GE Healthcare saw strong growth in both revenue and operating profit for its third quarter.
GE's Optison contrast approved for label change
GE Healthcare has received approval from the U.S. Food and Drug Administration for a label change for its Optison ultrasound contrast agent.
Dilon updates Navigator gamma probe
Molecular breast imaging developer Dilon Diagnostics has released a new version of its gamma probe system for sentinel lymph node biopsy.
Dilon highlights molecular breast tomo device at SNMMI
Molecular breast imaging developer Dilon Diagnostics is highlighting new molecular breast tomosynthesis technology at the Society of Nuclear Medicine...

Copyright © 2016 AuntMinnie.com

Last Updated hh 11/27/2016 11:17:14 AM

Facebook Twitter LinkedIn Email Print